PD-L1 and PD-L2 expression in colorectal cancer

Simple item page
dc.contributor.authorZeynep, Oen_US
dc.contributor.authorFunda, Cen_US
dc.contributor.authorEvrim, Yen_US
dc.contributor.authorDeniz, Aen_US
dc.contributor.authorBülent, Yen_US
dc.contributor.authorFatih, YN.en_US
dc.date.accessioned2023-08-10T07:33:18Z
dc.date.available2023-08-10T07:33:18Z
dc.date.issued2023-03
dc.description.abstractContext: The programmed death-1 (PD-1) is an immune checkpoint molecule that suppresses T-cell response. The binding of PD-1 to PD-L1/PD-L2 results cytokine production, and T-cell proliferation are reduced. Tumors expressing PD-L1 and PD-L2 escape from cytotoxic T-cells and are exposed to tumor progression. For this reason, immunotherapy has become a new option in the treatment of cancer. Aims: In this study, we examined the PD-L1 and PD-L2 expression in colorectal carcinoma (CRC), and evaluated the relationship between clinicopathological parameters and CD8+ T cells. Methods and Material: We evaluated CD8 expression in tumor-infiltrating lymphocytes and surrounding tumor lymphocytes with PD-L1, PD-L2 staining in tumor cells and immune cells formalin-fixed paraffin embedded samples of 124 patient diagnosed with CRC. Statistical Analysis Used: Pearson Chi-Square, Fisher Exact Chi-Square, and Pearson Exact Chi-Square analyses were used in the analysis of the cross tables. Survival distributions predicted Kaplan--Meier method and it was evaluated using log-rank statistics. Results: In our study, a significant correlation was found between PD-L1 expression and female sex and tumors with medullary morphology. No expression of PD-L2 was observed in tumors containing medullary morphology, and a statistically inverse relationship was observed between PD-L2 and the medullary component. PD-L1 positive tumor-infiltrating lymphocytes were determined to be an important predictor for recurrence-free survival. Conclusions: We believe that the evaluation of these parameters may be useful in the selection of patients who will benefit from immunotherapy in CRC cases.en_US
dc.identifier.affiliationsAtatürk Public Hospital, Pathology, Antalya, Turkeyen_US
dc.identifier.affiliationsDepartment of Pathology, Medical Faculty, Osmangazi University, Eski?ehir, Turkeyen_US
dc.identifier.affiliationsDepartment of Medical Oncology, Medical Faculty, Osmangazi University, Eski?ehir, Turkeyen_US
dc.identifier.affiliationsDepartment of General Surgery, Medical Faculty, Osmangazi University, Eski?ehir, Turkeyen_US
dc.identifier.citationZeynep O, Funda C, Evrim Y, Deniz A, Bülent Y, Fatih YN.. PD-L1 and PD-L2 expression in colorectal cancer. Indian Journal of Pathology & Microbiology. 2023 Mar; 66(1): 31-37en_US
dc.identifier.issn0377-4929
dc.identifier.issn0974-5130
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/223440
dc.languageenen_US
dc.publisherWolters Kluwer - Medknowen_US
dc.relation.issuenumber1en_US
dc.relation.volume66en_US
dc.source.urihttps://doi.org/10.4103/ijpm.ijpm_814_21en_US
dc.subjectColorectal canceren_US
dc.subjectimmunotherapyen_US
dc.subjectPD-L1en_US
dc.subjectPD-L2en_US
dc.titlePD-L1 and PD-L2 expression in colorectal canceren_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJPM2023v66n1p31.pdf
Size:
1.59 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Pathology & Microbiology